Table 1.
Clinical characteristics of patients with vHL syndrome
| Characteristic | All | Missense mutation | Truncation mutation |
P value (between two groups) |
|---|---|---|---|---|
| Number of patients | 94 | 84 | 10 | |
| Age (years) | 37.12 ± 16.39 | 37.30 ± 16.34 | 35.60 ± 17.59 | .759 |
| Sex | ||||
| Female | 49 (52.13%) | 44 (52.38%) | 5 (50.00%) | > .999 |
| Male | 45 (47.87%) | 40 (47.62%) | 5 (50.00%) | |
| Baseline | ||||
| Hemangioblastoma, brain | 53 (61.63%) | 47 (60.26%) | 6 (75.00%) | .705 |
| Median number | 2 (1,5) | 2 (1, 5) | 3.5 (1, 5) | .660 |
| Median volume (ml) | 22 (8, 35) | |||
| Renal cell carcinoma | 27 (30.00%) | 25 (31.25%) | 2 (20.00%) | .717 |
| Median number | 2 (1, 4) | 2(1, 3) | 3 (1, 5) | .730 |
| Median volume (ml) | 40 (24, 102) | 40 (25, 80) | 89.5 (24, 155) | .746 |
| Hemangioblastoma, spine | 43 (55.13%) | 40 (55.56%) | 3 (50.00%) | > .999 |
| Renal cysts (Kidney cysts) | 47 (52.22%) | 40 (50.00%) | 7 (70.00%) | .320 |
| Adrenal, pheochromocytoma | 25 (27.47%) | 22 (27.16%) | 3 (30.00%) | > .999 |
| Pancreas, serous cystadenoma | 28 (31.11%) | 23 (28.4%) | 5 (55.56%) | .130 |
| Pancreas, NET | 15 (16.67%) | 13 (16.05%) | 2 (22.22%) | .642 |
| Median FU duration (years) | ||||
| Hemangioblastoma, brain | 6.32 (3.16, 9.89) | 6.80 (3.35, 10.58) | 4.08 (2.29, 4.59) | .032 |
| Renal cell carcinoma | 6.12 (2.61, 11.27) | 6.18 (2.99, 11.33) | 4.94 (1.24, 6.83) | .170 |
NET Neuroendocrine tumor, FU Follow up